Patents by Inventor Nikolaj Blom
Nikolaj Blom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926852Abstract: The present invention relates to compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity for use in, e.g., animal feed. The present invention further relates to polypeptides having arabinofuranosidase activity, polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: May 28, 2021Date of Patent: March 12, 2024Assignee: Novozymes A/SInventors: Wei Peng, Ninfa Rangel Pedersen, Dan Pettersson, Jens Magnus Eklof, Soren Nymand-Grarup, Lorena G. Palmen, Rune Nygaard Monrad, Nikolaj Spodsberg, Mary Ann Stringer, Charlotte Blom, Lars Kiemer, Kristian Bertel Romer M. Krogh, Jesper Salomon
-
Patent number: 9845344Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: GrantFiled: March 30, 2005Date of Patent: December 19, 2017Assignee: HOBA THERAPEUTICS APSInventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Søren Brunak, Lars U. Wahlberg
-
Publication number: 20120252726Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: ApplicationFiled: April 11, 2011Publication date: October 4, 2012Applicant: NSGENE A/SInventors: Teit E. Johansen, Nikolaj Blom, Claus Hansen
-
Publication number: 20120184492Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: December 15, 2011Publication date: July 19, 2012Applicant: NsGene A/SInventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
-
Publication number: 20100234293Abstract: The invention relates to neublastinneurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: ApplicationFiled: October 27, 2009Publication date: September 16, 2010Applicant: NsGene A/SInventors: Teit E. Johansen, Nikolaj Blom, Claus Hansen
-
Publication number: 20090136552Abstract: Disclosed are NsG28, NsG30, NsG32 polypeptides, nucleic acids encoding NsG28, NsG30, NsG32 polypeptides, and antibodies that bind to NsG28, NsG30, NsG32 polypeptides as well as methods of making and using the same.Type: ApplicationFiled: August 1, 2005Publication date: May 28, 2009Inventors: Mette Gronborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
-
Publication number: 20090087474Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on secreted therapeutic proteins, NsG29 and NsG31. NsG29 and Ns31 are members of a newly identified family of growth factors with a specific cystein pattern and characterised by expression in the nervous system. The secreted growth factors have potential for the treatment of disorders of the nervous system. The invention also relates to bioactive NsG29 and NsG31 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: January 9, 2006Publication date: April 2, 2009Inventors: Thomas N. Petersen, Nikolaj Blom, Mette Gronborg, Philip Kusk, Soren Brunak, Teit E. Johansen, Lars U. Wahlberg
-
Publication number: 20080318853Abstract: The present invention relates to the field of diagnostic and therapeutic use of proteins and genes, in particular to the diagnostic and therapeutic use of a secreted human hormone/growth factor, Neublasmin, and use or the gene coding for Neublasmin in the diagnosis and treatment of testicular disorders, in particular diagnosis and treatment of germ cell tumours and infertility. The invention also relates to use of Neublasmin in the treatment of CNS disorders. Neublasmin is expressed at high levels in human adult testicles and in developing mouse testicles from pn 22 and onwards. Expression or Neublasmin is strongly up-regulated in carcinoma in situ. Expression is also seen in foetal and adult brain.Type: ApplicationFiled: November 4, 2005Publication date: December 25, 2008Applicant: NSGENE A/SInventors: Mette Gronborg, Nikolaj Blom
-
Publication number: 20080227703Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: ApplicationFiled: October 31, 2007Publication date: September 18, 2008Inventors: Teit E. Johansen, Nikolaj Blom, Claus Hansen
-
Publication number: 20070275026Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein. NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: March 30, 2005Publication date: November 29, 2007Applicant: NSGENE A/SInventors: Mette Gronborg, Philip Kusk, Nikolaj Blom, Thomas Petersen, Teit Johansen, Soren Brunak, Lars Wahlberg
-
Publication number: 20040259779Abstract: The present invention relates to novel biologically active, processed forms of the neuronal survival and growth factor protein denominated NSG3, in particular the pro-protein, the mature protein and core fragment of NSG3, as well as variants thereof. Also, the use of the novel polypeptides for treating or preventing a neurodegenerative disease, in particular an excitotoxic disease, a cancer, tissue injury, insufficient bone cartilage growth and maturation or a disease involving muscle in an animal is described.Type: ApplicationFiled: July 23, 2004Publication date: December 23, 2004Inventors: Teit Johansen, Nikolaj Blom, Claus Hansen
-
Publication number: 20040230043Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: ApplicationFiled: March 22, 2004Publication date: November 18, 2004Inventors: Teit E. Johansen, Nikolaj Blom, Claus Hansen
-
Patent number: 6734284Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: GrantFiled: September 15, 2000Date of Patent: May 11, 2004Assignee: NsGene A/SInventors: Teit E. Johansen, Nikolaj Blom, Claus Hansen
-
Patent number: 6593133Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: GrantFiled: July 2, 1999Date of Patent: July 15, 2003Assignee: NsGENE A/SInventors: Teit E. Johansen, Nikolaj Blom, Claus Hansen